Related Experiment Video

Updated: Jan 7, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K

Heart Transplantation: Is It Still the Gold Standard?

Tania Kakoudaki1, Sri Aurovind1, Anna Kydd1

  • 1Transplant Unit, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.

British Journal of Hospital Medicine (London, England : 2005)
|December 24, 2025
PubMed

Insights

Heart transplantation (HT) is the gold standard for advanced heart failure (AHF), but mechanical circulatory support via left ventricular assist devices (LVADs) offers a vital alternative. While HT survival is higher, donor organ scarcity impacts its widespread use.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Medical Technology

Background:

  • Advanced heart failure (AHF) presents significant challenges with poor patient prognosis.
  • Surgical interventions, including mechanical circulatory support (MCS) and heart transplantation (HT), have advanced AHF treatment.
  • Left ventricular assist device (LVAD) therapy is a key alternative to HT for select AHF patients.

Purpose of the Study:

  • To compare the efficacy and limitations of heart transplantation (HT) versus left ventricular assist device (LVAD) therapy in advanced heart failure (AHF).
  • To review current survival rates and quality of life considerations for both treatment modalities.
  • To discuss future directions in MCS and donor strategies for AHF management.

Main Methods:

  • Comparative analysis of survival data for HT and contemporary LVADs.
  • Review of quality of life outcomes and device-related complications.
  • Discussion of donor organ availability and emerging LVAD technologies.

Main Results:

  • Five-year survival post-HT is 72%, compared to 58-63% for contemporary LVADs.
  • HT offers a better quality of life and avoids device-related complications.
  • Donor organ availability remains a significant limitation for HT.

Conclusions:

  • Heart transplantation is the gold standard for carefully selected AHF patients, offering superior survival and quality of life.
  • LVAD therapy is an important and evolving alternative, particularly when donor organs are unavailable.
  • Future advancements in fully implantable LVADs and expanded donor strategies are crucial for optimizing AHF treatment.

Keywords:
heart failureheart transplantationleft ventricular assist device

More Related Videos

A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation09:12

A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation

Published on: April 27, 2019

10.0K
Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.9K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
310
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
431
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
360
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
304